Compare Main Street Capital Corporation (MAIN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs ResMed Inc. — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.09B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 6.3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and ResMed Inc. for 51 Days on average.
| MAIN | RMD | |
|---|---|---|
Market Cap | $5.09B | $31.89B |
Volume | 524,060 | 618,314 |
Sector | Financials | Health |
52-Week High | $64.60 | $277.88 |
52-Week Low | $49.63 | $182.82 |
Typical Hold Time | 88 Days | 51 Days |
Enterprise Value | $7.54B | $31.24B |
Dividend Yield | 5.84% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $592 million and net income of $493 million for 2025, with a net income margin of 83.36%. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. Analyst consensus is a Hold with a $58.33 price target, indicating modest upside potential.
Outlook: MAIN offers a stable dividend history and strong profitability, but faces headwinds from softening revenue projections for 2026 and negative operating cash flow. Risks include earnings volatility and high valuation multiples. The stock presents a cautious opportunity for income-focused investors, balanced by near-term fundamental pressures.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
